Inclusion Criteria

Inclusion criteria:

- Confirmed diagnosis of symptomatic MM based on standard criteria.

- No prior or current systemic therapy for MM, including steroids.

- At least 18 years and less than 65 years of age.

- Presence of quantifiable M protein in serum (e.g. greater than 1 g/dL for IgG MM,
greater than 0.5 g/dL of IgA or IgD MM) or urine (e.g. greater than 200 mg/day for BJ
MM).

- Karnofsky performance status (PS) at least 60%.

- Willing and able to comply with the protocol requirements.

- Agreement from both male and female patients to follow the risk management program
established for the prevention of pregnancy, including double methods for
contraception and beta-HCG tests for women of childbearing potential and
contraception for males.

- Adequate organ function, including heart, liver, kidney (serum creatinine less than 2
mg/dL)

- Platelet count at least 70 x 10/mcL and absolute neutrophil count at least 1 x 10/mcl

Exclusion criteria:

- Diagnosis of asymptomatic MM or of MGUS based on standard criteria.

- Diagnosis of non-secretory MM.

- Diagnosis of AL Amyloidosis.

- Prior or current systemic therapy for MM, including steroids (with exception of
bisphosphonates).

- Patient has received other investigational drugs within 30 days before enrollment.

- Female subjects pregnant or breastfeeding

- Patient has Grade 2 or higher peripheral neuropathy (NCI criteria).

- Patient has a prior history of thrombosis or venous thromboembolism or pulmonary
embolism.

- Patient has a previous diagnosis of antiphospholipid antibodies or lupus
anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin,
protein C or S deficiency.

- Patient has a clear indication to receive a specific other anti-platelet therapy
(e.g. clopidogrel, ticlopidine).

- Patient has a clear indication to receive long-term anticoagulant therapy (e.g.
prosthetic heart valve, atrial fibrillation).

- Active bleeding or high risk of bleeding (gastrointestinal bleeding within the past
12 months; endoscopic diagnosis of peptic ulcer disease or ulcerative esophagitis
within the past 6 months unless there is documented endoscopic evidence of healing;
intracranial bleeding within the past year; amyloidosis; known bleeding diathesis).

- Seropositive for HIV, or active hepatitis A, B or C infection.

- Poorly controlled hypertension or diabetes mellitus (if receiving antidiabetic
agents, subjects must be on a stable dose for at least 3 months before the start of
therapy) or other serious medical or psychiatric conditions that could interfere with
adherence to or completion of this study.

- Patient has hypersensitivity to bortezomib, boron or mannitol.

- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study

- Previous or concurrent malignancies at other sites, with the exception of
appropriately treated localized epithelial skin or cervical cancer. Patients with
remote histories (>5 years) of other cured tumors may be entered.

- Receipt of extensive radiation therapy, systemic chemotherapy, or other
antineoplastic therapy within 4 weeks before enrolment.